4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
https://www.fool.com/investing/2024/04/14/nasdaq-bull-market-4-growth-stocks-regret-not-buy/?source=iedfolrf0000001
Apr 14, 2024 - Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.
0
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
https://www.zacks.com/stock/news/2254638/astrazeneca-s-azn-fasenra-gets-fda-nod-for-asthma-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254638
Apr 12, 2024 - The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253429
Apr 10, 2024 - Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
0
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
0
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
https://www.zacks.com/stock/news/2251823/astrazeneca-s-azn-enhertu-gets-fda-nod-for-solid-tumors?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251823
Apr 08, 2024 - FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
0
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2251455/astrazeneca-azn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2251455
Apr 05, 2024 - Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session.
0
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
0
Top Research Reports for Berkshire Hathaway, Procter & Gamble & Adobe
https://www.zacks.com/commentary/2249662/top-research-reports-for-berkshire-hathaway-procter-gamble-adobe?cid=CS-ZC-FT-research_daily-2249662
Apr 03, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Procter & Gamble Company (PG) and Adobe Inc. (ADBE).
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2249245/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2249245
Apr 02, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
0
Page 1>